Literature DB >> 12795332

New advances on prostate carcinogenesis and therapies: involvement of EGF-EGFR transduction system.

Murielle Mimeault1, Nicole Pommery, Jean-Pierre Hénichart.   

Abstract

The prostate cancers (PCs) are among the major causes of death because therapeutic treatments are not effective against advanced and metastatic forms of this cellular hyperproliferative disorder. In fact, although androgen-deprivation therapies permit to cure localized PC forms, the metastatic PC cells have acquired multiple functional features that confer to them resistance to ionizing radiations and anticarcinogenic drugs currently used in therapy. The present review describes last advances on molecular mechanisms that might be responsible for sustained growth and survival of PC cells. In particular, emphasis is on intracellular signaling cascades which are involved in the mitogenic and antiapoptotic effects of epidermal growth factor EGF-EGFR system. Of therapeutic interest, recent advances and prospects for development of new treatments against incurable forms of metastatic PC forms are also discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12795332     DOI: 10.1080/0897719031000094921

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  14 in total

1.  External Qi of Yan Xin Qigong induces G2/M arrest and apoptosis of androgen-independent prostate cancer cells by inhibiting Akt and NF-kappa B pathways.

Authors:  Xin Yan; Hua Shen; Hongjian Jiang; Chengsheng Zhang; Dan Hu; Jun Wang; Xinqi Wu
Journal:  Mol Cell Biochem       Date:  2007-12-16       Impact factor: 3.396

2.  7,3',4'-Trihydroxyisoflavone inhibits epidermal growth factor-induced proliferation and transformation of JB6 P+ mouse epidermal cells by suppressing cyclin-dependent kinases and phosphatidylinositol 3-kinase.

Authors:  Dong Eun Lee; Ki Won Lee; Nu Ry Song; Sang Kwon Seo; Yong-Seok Heo; Nam Joo Kang; Ann M Bode; Hyong Joo Lee; Zigang Dong
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

Review 3.  Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance.

Authors:  Shaun McKenzie; Natasha Kyprianou
Journal:  J Cell Biochem       Date:  2006-01-01       Impact factor: 4.429

Review 4.  Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Anticancer Agents Med Chem       Date:  2010-02       Impact factor: 2.505

5.  Exogenous p27KIP1 expression induces anti-tumour effects and inhibits the EGFR/PI3K/Akt signalling pathway in PC3 cells.

Authors:  Jun Chen; Dan Xia; Jin-Dan Luo; Ping Wang
Journal:  Asian J Androl       Date:  2009-09-07       Impact factor: 3.285

6.  EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling.

Authors:  Alyse M DeHaan; Natalie M Wolters; Evan T Keller; Kathleen M Woods Ignatoski
Journal:  Prostate       Date:  2009-04-01       Impact factor: 4.104

7.  Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.

Authors:  Lorella Bonaccorsi; Sara Marchiani; Monica Muratori; Gianni Forti; Elisabetta Baldi
Journal:  J Cancer Res Clin Oncol       Date:  2004-07-16       Impact factor: 4.553

Review 8.  Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.

Authors:  Murielle Mimeault; Parmender P Mehta; Ralph Hauke; Surinder K Batra
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

Review 9.  Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.

Authors:  M Mimeault; S K Batra
Journal:  Panminerva Med       Date:  2008-03       Impact factor: 5.197

Review 10.  Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies.

Authors:  M Mimeault; R Hauke; S K Batra
Journal:  Clin Pharmacol Ther       Date:  2007-09-05       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.